Pharming Group

Pharming Group reported Q2 revenue of $90.2m, down 3% year‑over‑year, and lowered its 2026 revenue guidance to $375m–$395m while trimming operating expenses by $15m. RUCONEST sales fell 10% y/y to $72.3m but management expects patient metrics to support stabilization and a return to growth in H2 2026. Joenja revenue rose 40% to $17.9m, with U.S. pediatric dose filings and launches in Germany and Japan supporting an anticipated high‑30% annual growth for 2026. Two Phase II leniolisib readouts in broader primary immunodeficiency populations are expected in Q4, while cash and marketable securities stood at $159.5m at quarter end. » More on finance.yahoo.com

Pharming reported Q1 2026 revenue of USD 72.4 million (-8%) and a share-price plunge after the release. Joenja revenues rose 34% to USD 14.1 million but could not offset a 15% decline in RUCONEST to USD 58.4 million. Adjusted operating income worsened to a loss of USD 4.9 million, and cash and cash equivalents amounted to USD 171.8 million. Management confirmed the full-year guidance of USD 405–425 million and continues to pursue international expansion and indication expansion for Joenja. » More on de.investing.com

Pharming reports 2025 revenue of $376.1 million (+27%) and its first adjusted operating profit of $36.4 million. Drivers were RUCONEST ($317.9 million) and Joenja ($58.2 million); the quarter delivered $106.5 million in revenue and an adjusted operating profit of $6.5 million. The company expects 2026 revenue of $405–425 million with operating expenses of $330–335 million and cites near-term regulatory catalysts, in particular an FDA Type A meeting on pediatric approval of Joenja. Pharming is also expanding its pipeline (including Napazimon/KL1333) and plans clinical study advances and recruitment completions in the second half of 2026. » More on de.investing.com

Pharming Group’s stock rose to a 52-week high of 18.19 USD and is up 79.73% year-to-date and 70.66% over the past year. InvestingPro reports a gross profit margin of 89.9% and rates the company’s financial position as "GREAT." The FDA has approved the sNDA for Leniolisib to treat children aged 4 to 11 with APDS, extending the approval of the oral PI3Kδ inhibitor to a younger patient group. The combination of regulatory progress and strong share-price momentum underscores Pharming Group’s strengthened market position. » More on de.investing.com

Pharming Group’s stock climbed to a 52-week high of around $17.89–17.94 and has gained about 90.24% year-to-date (53.31% over six months). InvestingPro rates the financial situation as “GREAT,” highlighting a gross profit margin of 89.9% and revenue growth of 26.78%, but notes the stock may be trading above fair value. In addition, the FDA approved the supplemental application for leniolisib, making the treatment available for children aged 4 to 11 with APDS. » More on de.investing.com